Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Placebo-controlled, Double-blind, Parallel-group, Multicentre, Phase IIa Study to Explore the Relationship Between QTcF Interval at First Dose (Loading Dose) and at Steady State After Treatment With AZD1305 Extended-release Tablets or Placebo When Given to Patients With Documented AF

NCT00643448 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00643448
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00643448 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Placebo-controlled, Double-blind, Parallel-group, Multicentre, Phase IIa Study to Explore the Relationship Between QTcF Interval at First Dose (Loading Dose) and at Steady State After Treatment With AZD1305 Extended-release Tablets or Placebo When Given to Patients With Documented AF
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2008
Completion date
August 31, 2008
Enrollment
65 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation